Mario Scarpa

Mario Scarpa

Auto-generated profile, based on publicly available information

Mario Scarpa

University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 February 2024 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
JLJonelle K. Lee
Jonelle K. Lee
ACAditi Chatterjee
Aditi Chatterjee
MSMario Scarpa
Mario Scarpa
CBChristopher M. Bailey
Christopher M. Bailey
SNSandrine Niyongere
Sandrine Niyongere
BRBaer M R
Baer M R
Acute myeloid leukemia (AML) with fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) has poor outcomes. FLT3-ITD drives constitutive and aberrant FLT3 signaling, activating STAT5 and upregulating the downstream oncogenic serine/threonine kinase Pim-1. FLT3 inhibitors are in clinical use, but with limited and transient efficacy. We previously showed that concurrent treatment with Pim and FLT3 inhibitors increases apoptosis induction in FLT3-ITD–expressing cells through posttranslational downregulation of Mcl-1. Here we further elucidate the mechanism of action of this dual targeting strategy. Cytotoxicity, apoptosis and protein expression and turnover were measured in FLT3-ITD–expressing cell lines and AML patient blasts treated with the FLT3 inhibitor gilteritinib and/or the Pim inhibitors AZD1208 or TP-3654. Pim inhibitor and gilteritinib cotreatment increased apoptosis induction, produced synergistic cytotoxicity, downregulated c-Myc protein expression, earlier than Mcl-1, increased turnover of both proteins, which was rescued by proteasome inhibition, and increased efficacy and prolonged survival in an in vivo model. Gilteritinib and Pim inhibitor cotreatment of Ba/F3-ITD cells infected with T58A c-Myc or S159A Mcl-1 plasmids, preventing phosphorylation at these sites, did not downregulate these proteins, increase their turnover or increase apoptosis induction. Moreover, concurrent treatment with gilteritinib and Pim inhibitors dephosphorylated (activated) the serine/threonine kinase glycogen synthase kinase-3β (GSK-3β), and GSK-3β inhibition prevented c-Myc and Mcl-1 downregulation and decreased apoptosis induction. The data are consistent with c-Myc T58 and Mcl-1 S159 phosphorylation by activated GSK-3β as the mechanism of action of gilteritinib and Pim inhibitor combination treatment, further supporting GSK-3β activation as a therapeutic strategy in FLT3-ITD AML. Significance: FLT3-ITD is present in 25% of in AML, with continued poor outcomes. Combining Pim kinase inhibitors with the FDA-approved FLT3 inhibitor gilteritinib increases cytotoxicity in vitro and in vivo through activation of GSK-3β, which phosphorylates and posttranslationally downregulates c-Myc and Mcl-1. The data support efficacy of GSK-3β activation in FLT3-ITD AML, and also support development of a clinical trial combining the Pim inhibitor TP-3654 with gilteritinib.

16 February 2024
Verified
Other
Open access
JLJonelle K. Lee
Jonelle K. Lee
ACAditi Chatterjee
Aditi Chatterjee
MSMario Scarpa
Mario Scarpa
CBChristopher M. Bailey
Christopher M. Bailey
SNSandrine Niyongere
Sandrine Niyongere
BRBaer M R
Baer M R
S159A-mutated Mcl-1 confers resistance to Mcl-1 downregulation and to apoptosis induction by gilteritinib and AZD1208 combination treatment. A, Ba/F3-ITD cells infected with pBabe-Flag hMcl-1-S159A, containing Mcl-1 with a mutation changing serine to alanine at residue 159, preventing phosphorylation, pBabe-Flag hMcl-1 plasmid, containing wild-type Mcl-1, or pBABE-puro empty vector were treated with either gilteritinib and AZD1208 or DMSO control, and serial samples were immunoblotted for Mcl-1 and vinculin loading control. Densitometric analysis is also shown. B, To measure Mcl-1 protein turnover, cells were pretreated with CHX for 1 hour and then treated with gilteritinib and AZD1208 (+) or DMSO control (−). Serial samples were immunoblotted for c-Myc and vinculin loading control. Densitometric analysis was performed. Mcl-1 was normalized to vinculin and 50% protein turnover timepoints were determined to be 1.75 versus more than 2 hours for gilteritinib and AZD1208 versus DMSO control for empty vector, 1.27 versus 1.6 for wild-type Mcl-1 and more than 2 hours for both for S159A Mcl-1. C, Cells infected with pBabe-Flag hMcl-1-S159A, pBabe-Flag hMcl-1 or pBABE-puro empty vector control were treated with gilteritinib and/or AZD1208, or DMSO control, for 48 hours, and apoptosis was measured. Apoptosis induction by gilteritinib and AZD1208 combination was significantly reduced in cells infected with pBABE-puroS159A compared with empty vector control (**, P < 0.001).

16 February 2024
Verified
Other
Open access
JLJonelle K. Lee
Jonelle K. Lee
ACAditi Chatterjee
Aditi Chatterjee
MSMario Scarpa
Mario Scarpa
CBChristopher M. Bailey
Christopher M. Bailey
SNSandrine Niyongere
Sandrine Niyongere
BRBaer M R
Baer M R
Concurrent Pim and FLT3 inhibitor treatment activates GSK-3β, and GSK-3β inhibitor abrogates c-Myc and Mcl-1 downregulation. A, Ba/F3-ITD cells and FLT3-ITD AML patient blasts were treated with gilteritinib and/or AZD1208, or DMSO control, and expression of c-Myc, Mcl-1, p-GSK-3α,β (S9/S21), GSK-3α,β and β-actin or vinculin loading control at serial time points was measured by immunoblotting. Data in A are shown graphically in B. C, Ba/F3-ITD and MV4-11 cells and FLT3-ITD AML patient blasts were treated with gilteritinib and/or AZD1208, or DMSO control, with and without the GSK-3β inhibitor TC G-24 at 20 nM, and expression of c-Myc, Mcl-1, p-GSK-3α,β (S9/S21), GSK-3α,β and β-actin or vinculin loading control was measured at serial time points by immunoblotting. Data in C are shown graphically in D.


16 February 2024
Verified
Other
Open access
JLJonelle K. Lee
Jonelle K. Lee
ACAditi Chatterjee
Aditi Chatterjee
MSMario Scarpa
Mario Scarpa
CBChristopher M. Bailey
Christopher M. Bailey
SNSandrine Niyongere
Sandrine Niyongere
BRBaer M R
Baer M R
Concurrent Pim and FLT3 inhibition downregulates c-Myc prior to Mcl-1 protein expression. A, Ba/F3-ITD, MV4-11 and MOLM-14 cells and blasts from a patient with FLT3-ITD AML plated at 1 × 105 cells/mL were treated with gilteritinib (15 nmol/L for Ba/F3-ITD and patient blasts and 10 nmol/L for MV4-11 and MOLM-14) and/or 1 µmol/L AZD1208, or DMSO control. B, Ba/F3-ITD, MV4-11, and MOLM-14 cells were also treated with gilteritinib and/or 1 µmol/L TP-3654, or DMSO control. c-Myc, Mcl-1, and vinculin loading control protein levels were measured by immunoblotting in samples collected at serial timepoints. Data in A and B are shown graphically in C and D, respectively.

16 February 2024
Verified
Other
Open access
JLJonelle K. Lee
Jonelle K. Lee
ACAditi Chatterjee
Aditi Chatterjee
MSMario Scarpa
Mario Scarpa
CBChristopher M. Bailey
Christopher M. Bailey
SNSandrine Niyongere
Sandrine Niyongere
BRBaer M R
Baer M R
Acute myeloid leukemia (AML) with fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) has poor outcomes. FLT3-ITD drives constitutive and aberrant FLT3 signaling, activating STAT5 and upregulating the downstream oncogenic serine/threonine kinase Pim-1. FLT3 inhibitors are in clinical use, but with limited and transient efficacy. We previously showed that concurrent treatment with Pim and FLT3 inhibitors increases apoptosis induction in FLT3-ITD–expressing cells through posttranslational downregulation of Mcl-1. Here we further elucidate the mechanism of action of this dual targeting strategy. Cytotoxicity, apoptosis and protein expression and turnover were measured in FLT3-ITD–expressing cell lines and AML patient blasts treated with the FLT3 inhibitor gilteritinib and/or the Pim inhibitors AZD1208 or TP-3654. Pim inhibitor and gilteritinib cotreatment increased apoptosis induction, produced synergistic cytotoxicity, downregulated c-Myc protein expression, earlier than Mcl-1, increased turnover of both proteins, which was rescued by proteasome inhibition, and increased efficacy and prolonged survival in an in vivo model. Gilteritinib and Pim inhibitor cotreatment of Ba/F3-ITD cells infected with T58A c-Myc or S159A Mcl-1 plasmids, preventing phosphorylation at these sites, did not downregulate these proteins, increase their turnover or increase apoptosis induction. Moreover, concurrent treatment with gilteritinib and Pim inhibitors dephosphorylated (activated) the serine/threonine kinase glycogen synthase kinase-3β (GSK-3β), and GSK-3β inhibition prevented c-Myc and Mcl-1 downregulation and decreased apoptosis induction. The data are consistent with c-Myc T58 and Mcl-1 S159 phosphorylation by activated GSK-3β as the mechanism of action of gilteritinib and Pim inhibitor combination treatment, further supporting GSK-3β activation as a therapeutic strategy in FLT3-ITD AML.